Bacillus Calmette–Guerin (BCG) intravesical instillation therapy is the most effective adjuvant therapy for bladder cancer after transurethral resection of bladder tumor. However, Bacillus Calmette–Guerin therapy is associated with a high risk o...
Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16%, complete what is seen as a gold standard treatment. To understand why ...
About 4 to 6 hours after treatment, you may have bladder symptoms such as sudden urges to urinate, frequent urination, stomach discomfort, bloating, and possibly loss of bladder control. Tell your doctor right away if these side effects last for longer than 2 or 3 days. ...
Do not drink any fluids for 4 hours before treatment. The medication is left in thebladderfor up to 2 hours and then released by urinating. Follow your doctor's instructions carefully. There may be some burning pain when you first urinate. Since the urine contains live bacteria that may inf...
Use caution in patients with small bladder capacity Postpone intravesical instillation duringantibiotictherapy Vaccination not recommended for patients with positivePPDreaction Not for the treatment of active tuberculosis or prevention of cancer May not result in effective immunity in all patients ...
-a treatment that controlssuperficial bladder cancer, particularlycarcinoma in situ. I was surprised tolearn that an ancient vaccine, originallydesigned to prevent tuberculosis (TB), isemployed for a completely unrelatedindication and is the current treatment ofchoice for bladder cancer. I thought that...
Findings In this cohort study of 6467 patients with non–muscle-invasive bladder cancer, treatment with intravesical BCG vaccine was associated with a reduced risk of ADRD in the presence of death as a competing risk. However, the risk differences varied with time. Meaning The findings of this...
Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment Cancer immunotherapy has rapidly become the fourth mainstream treatment alternative after surgery, radiotherapy, and chemotherapy, with some promising resu... S Zeng,S Xing,Y Zhang,... - Journal of Zhejiang University-SC...
Agents that target PD-1 and PD-L1 have been developed in the treatment of bladder cancer (BC). However, the diversity of immune cell infiltration in non-muscle-invasive BC (NMIBC) and the dynamics of the microenvironment as it progresses to muscle-invasive/metastatic disease remains unknown. ...
BCG-RIVM strain was used in many treatment protocols for non-muscle invasive bladder cancer only as induction courses. Cho et al. (Anticancer Res 2012) compared BCG-RIVM induction and 'standard' maintenance (Lamm et al., J Urol. 2000) to mitomycin C. They found no statistically significant ...